Nephrogenic Fibrosing Dermopathy: Are ACE Inhibitors the Missing Link?

Quantification of gadolinium in nephrogenic systemic fibrosis: Re-examination of a reported cohort with analysis of clinical factors

“…30 At least two series have reported a paucity of ACE-inhibitor use in some patients affected by NSF. 31,32 However, in our series, one half of patients were taking an ACE inhibitor at the time of exposure to gadodiamide, suggesting that if any protective effect exists, it is incomplete in nature.…”

Quantification of gadolinium in nephrogenic systemic fibrosis: Re-examination of a reported cohort with analysis of clinical factors

“…30 At least two series have reported a paucity of ACE-inhibitor use in some patients affected by NSF. 31,32 However, in our series, one half of patients were taking an ACE inhibitor at the time of exposure to gadodiamide, suggesting that if any protective effect exists, it is incomplete in nature.…”

Safety update on the possible causal relationship between gadolinium‐containing MRI agents and nephrogenic systemic fibrosis

“…Its use dramatically increased after the publication of the Dialysis Outcomes Quality Initiative guidelines for anemia management in 1997 (http://www.kidney.org/professionals/KDOQI) (10). Alternatively, a report correlating the decreasing plasma levels of transforming growth factor (TGF)-␤ after plasmapheresis with the amelioration of clinical signs of NSF in a few patients (11) is consistent with the hypothesis that a lack of treatment with an angiotensin converting enzyme (ACE) inhibitor may at least partially be linked to the development of this disease (12).…”

Nephrogenic systemic fibrosis following hair-dye ingestion induced acute renal failure

“…[5] The antihypertensive drugs, especially angiotensinconverting enzyme inhibitors which is extensively used in these patients is considered as one of the factors. [6] Erythropoietin used in patients with endstage renal disease is known to have profibrogenic and proinflammatory properties. [7] Grobner was the first to recognize the relation between the onset of NSF and exposure to gadolinium (gd) used as a contrast agent with MRI.…”

Quantification of gadolinium in nephrogenic systemic fibrosis: Re-examination of a reported cohort with analysis of clinical factors

“…30 At least two series have reported a paucity of ACE-inhibitor use in some patients affected by NSF. 31,32 However, in our series, one half of patients were taking an ACE inhibitor at the time of exposure to gadodiamide, suggesting that if any protective effect exists, it is incomplete in nature.…”

Safety update on the possible causal relationship between gadolinium‐containing MRI agents and nephrogenic systemic fibrosis

“…Its use dramatically increased after the publication of the Dialysis Outcomes Quality Initiative guidelines for anemia management in 1997 (http://www.kidney.org/professionals/KDOQI) (10). Alternatively, a report correlating the decreasing plasma levels of transforming growth factor (TGF)-␤ after plasmapheresis with the amelioration of clinical signs of NSF in a few patients (11) is consistent with the hypothesis that a lack of treatment with an angiotensin converting enzyme (ACE) inhibitor may at least partially be linked to the development of this disease (12).…”

Nephrogenic systemic fibrosis following hair-dye ingestion induced acute renal failure

“…[5] The antihypertensive drugs, especially angiotensinconverting enzyme inhibitors which is extensively used in these patients is considered as one of the factors. [6] Erythropoietin used in patients with endstage renal disease is known to have profibrogenic and proinflammatory properties. [7] Grobner was the first to recognize the relation between the onset of NSF and exposure to gadolinium (gd) used as a contrast agent with MRI.…”

Quantification of gadolinium in nephrogenic systemic fibrosis: Re-examination of a reported cohort with analysis of clinical factors

“…30 At least two series have reported a paucity of ACE-inhibitor use in some patients affected by NSF. 31,32 However, in our series, one half of patients were taking an ACE inhibitor at the time of exposure to gadodiamide, suggesting that if any protective effect exists, it is incomplete in nature.…”

Safety update on the possible causal relationship between gadolinium‐containing MRI agents and nephrogenic systemic fibrosis

“…Its use dramatically increased after the publication of the Dialysis Outcomes Quality Initiative guidelines for anemia management in 1997 (http://www.kidney.org/professionals/KDOQI) (10). Alternatively, a report correlating the decreasing plasma levels of transforming growth factor (TGF)-␤ after plasmapheresis with the amelioration of clinical signs of NSF in a few patients (11) is consistent with the hypothesis that a lack of treatment with an angiotensin converting enzyme (ACE) inhibitor may at least partially be linked to the development of this disease (12).…”

Nephrogenic systemic fibrosis following hair-dye ingestion induced acute renal failure

“…[5] The antihypertensive drugs, especially angiotensinconverting enzyme inhibitors which is extensively used in these patients is considered as one of the factors. [6] Erythropoietin used in patients with endstage renal disease is known to have profibrogenic and proinflammatory properties. [7] Grobner was the first to recognize the relation between the onset of NSF and exposure to gadolinium (gd) used as a contrast agent with MRI.…”